2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension : web addenda by GALIE, Nazzareno et al.
2015 ESC/ERS Guidelines for the
diagnosis and treatment of pulmonary
hypertension – web addenda
Nazzareno Galiè1 (ESC Chairperson), Marc Humbert2 (ERS Chairperson),
Jean-Luc Vachiery3, Simon Gibbs1, Irene Lang1, Adam Torbicki1,
Gérald Simonneau2, Andrew Peacock2, Anton Vonk Noordegraaf2,
Maurice Beghetti4, Ardeschir Ghofrani2, Miguel Angel Gomez Sanchez1,
Georg Hansmann4, Walter Klepetko3, Patrizio Lancellotti1, Marco Matucci5,
Theresa McDonagh1, Luc A. Pierard1, Pedro T. Trindade1, Maurizio Zompatori6
and Marius Hoeper2
The Joint Task Force for the Diagnosis and Treatment of Pulmonary
Hypertension of the European Society of Cardiology (ESC) and of the European
Respiratory Society (ERS)
Endorsed by: Association for European Paediatric and Congenital Cardiology
(AEPC), International Society for Heart and Lung Transplantation (ISHLT)
Affiliations: 1Representing the European Society of Cardiology. 2Representing the European Respiratory
Society. 3Representing the International Society for Heart and Lung Transplantation. 4Representing the
Association for European Paediatric and Congenital Cardiology. 5Representing the European League Against
Rheumatism. 6Representing the European Society of Radiology. A full list of collaborators and document
reviewers can be found in the Appendix.
Correspondence: Nazzareno Galiè, Dept of Experimental, Diagnostic and Specialty Medicine–DIMES,
University of Bologna, Via Massarenti 9, 40138 Bologna, Italy. E-mail: nazzareno.galie@unibo.it
Marc Humbert, Service de Pneumologie, Hôpital Bicêtre, Université Paris-Sud, Assistance Publique Hôpitaux
de Paris, 78 rue du Général Leclerc, 94270 Le Kremlin-Bicêtre, France. E-mail: marc.humbert@aphp.fr
The content of these European Society of Cardiology (ESC) and European Respiratory Society (ERS) Guidelines has
been published for personal and educational use only. No commercial use is authorized. No part of the ESC/ERS
Guidelines may be translated or reproduced in any form without written permission from the ESC and/or ERS.
Permission can be obtained upon submission of a written request to Oxford University Press, the publisher of the
European Heart Journal or from the European Respiratory Journal and the party authorized to handle such permissions
on behalf of the ESC and ERS.
This article is being published concurrently in the European Heart Journal and the European Respiratory Journal. The
articles are identical except for minor stylistic and spelling differences in keeping with each journal’s style. Either
citation can be used when citing this article.
Conflict of interest: Disclosures can be found alongside the online version of this article at erj.ersjournals.com
Published on behalf of the European Society of Cardiology. All rights reserved. © 2015 European Society of Cardiology





Pathology of pulmonary hypertension
Different pathological features characterise the diverse clinical pulmonary hypertension (PH) groups
[51, 52].
• Group 1, pulmonary arterial hypertension (PAH): pathological changes predominantly affect the distal
pulmonary arteries (<500 μm) with medial hypertrophy, intimal proliferative and fibrotic changes, adventitial
thickening with mild to moderate perivascular inflammatory infiltrates and lymphoid neogenesis, complex
lesions (plexiform, dilated lesions) and thrombotic lesions. Pulmonary veins are classically unaffected.
• Group 1′: includes mainly pulmonary veno-occlusive disease (PVOD) involving septal veins and
pre-septal venules with occlusive fibrotic lesions, venous muscularization, patchy capillary proliferation
with pulmonary capillary haemangiomatosis (PCH), pulmonary oedema, occult alveolar haemorrhage,
lymphatic dilatation, lymph node enlargement (vascular transformation of the sinus) and inflammatory
infiltrates. Distal pulmonary arteries are affected by medial hypertrophy and intimal fibrosis.
• Group 1″: persistent pulmonary hypertension of the newborn (PPHN) is characterized by changes in
vasoreactivity and wall structure and decreases in pulmonary vascular density with reduced
alveolarisation.
• Group 2: PH due to left heart disease (LHD) is characterised by enlarged and thickened pulmonary
veins, pulmonary capillary dilatation, interstitial oedema, alveolar haemorrhage and lymphatic vessel
and lymph node enlargement. Distal PA may be affected by medial hypertrophy and intimal fibrosis.
• Group 3: PH due to lung diseases and/or hypoxaemia is characterized by medial hypertrophy, intimal
obstructive proliferation of the distal pulmonary artery (PA) and muscularisation of arterioles. A variable
degree of destruction of the vascular bed in emphysematous or fibrotic areas may also be present.
• Group 4: PH due to chronic PA obstruction: chronic thromboembolic pulmonary hypertension
(CTEPH) lesions include organized thrombi tightly attached to the medial layer in the elastic PA,
replacing the normal intima. These may occlude the lumen or form different grades of stenosis, webs
and bands [53]. A pulmonary microvascular disease can develop in the non-occluded and occluded
areas that has similarities with PAH (with the exception of uncommon plexiform lesions in CTEPH)
and patchy post-capillary remodelling related to bronchial-to-pulmonary venous shunting [54, 55].
Collateral vessels from the systemic circulation (from bronchial, costal, diaphragmatic and coronary
arteries) can grow to reperfuse areas distal to complete obstructions.
• Group 5: PH with unclear and/or multifactorial mechanisms includes heterogeneous conditions with
different pathological pictures.
Pathobiology of pulmonary hypertension
Different pathobiological features [56–58] characterise the diverse clinical PH groups.
• Group 1: PAH has a multifactorial pathobiology. Excessive vasoconstriction has been related to
abnormal function or expression of potassium channels in the smooth muscle cells and to endothelial
dysfunction leading to chronically impaired production of vasodilator and antiproliferative agents such
as nitric oxide (NO) and prostacyclin, along with overexpression of vasoconstrictor and proliferative
substances such as thromboxane A2 and endothelin-1. Many of these abnormalities both elevate
vascular tone and promote vascular remodelling by proliferative changes involving endothelial and
smooth muscle cells as well as fibroblasts and pericytes. Growth factors such as platelet-derived growth
factor, fibroblast growth factor, transforming growth factor β (TGFβ) and bone morphogenic proteins
play a role in the remodelling process. Reduced bone morphogenetic protein receptor 2 (BMPR2)
expression contributes to the pathobiology of heritable and other forms of PAH. Other cell types
(inflammatory cells and platelets) and mediators (cytokines, chemokines, serotonin, etc.) play a role in
PAH. Prothrombotic abnormalities have been demonstrated in PAH patients and thrombi are present in
Disclaimer: The ESC/ERS Guidelines represent the views of the ESC and ERS and were produced after careful
consideration of the scientific and medical knowledge and the evidence available at the time of their publication. The
ESC and ERS are not responsible in the event of any contradiction, discrepancy and/or ambiguity between the ESC/ERS
Guidelines and any other official recommendations or guidelines issued by the relevant public health authorities, in
particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the
ESC/ERS Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the
implementation of preventive, diagnostic or therapeutic medical strategies; however, the ESC/ERS Guidelines do not
override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate
decisions in consideration of each patient’s health condition and in consultation with that patient and, where
appropriate and/or necessary, the patient’s caregiver. Nor do the ESC/ERS Guidelines exempt health professionals from
taking into full and careful consideration the relevant official updated recommendations or guidelines issued by the
competent public health authorities, in order to manage each patient’s case in light of the scientifically accepted data
pursuant to their respective ethical and professional obligations. It is also the health professional’s responsibility to
verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.
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both the small distal pulmonary arteries and in proximal elastic pulmonary arteries. Autoimmunity is
present in subgroups of PAH patients, as suggested by circulating autoantibody recognizing pulmonary
vascular cells and detection of lymphoid neogenesis in the lungs of idiopathic PAH (IPAH) patients.
• Group 1′: In PVOD, bi-allelic EIF2AK4 mutations, inflammation and exposure to toxic agents induce
oxidative and inflammatory injuries.
• Group 1″: In PPHN, endothelial cell dysfunction (with decreased NO production and activity) and
impaired angiogenic mechanisms underlie abnormalities of lung vascular growth.
• Group 2: PH due to LHD: The mechanisms responsible for the increase in pulmonary arterial pressure
(PAP) include passive backward transmission of the pressure elevation (isolated post-capillary PH,
Table 3). In these cases pulmonary vascular resistance (PVR) is within the normal range. In other
circumstances the elevation of PAP is greater than that of the pulmonary artery wedge pressure
(PAWP), leading to an increase in PVR (combined post-capillary and pre-capillary PH, Table 3). The
Web Table I Condensed clinical classification of pulmonary
hypertension (updated from Simonneau et al. [1])
1. Pulmonary arterial hypertension (PAH)
2. Pulmonary hypertension due to left heart disease
3. Pulmonary hypertension due to lung diseases and/or
    hypoxia
4. Chronic thromboembolic pulmonary hypertension
    and other pulmonary artery obstructions
5. Pulmonary hypertension with unclear and/or
    multifactorial mechanisms
1’. Pulmonary veno-occlusive disease and/or pulmonary capillary    
haemangiomatosis
1”. Persistent pulmonary hypertension of the newborn
1.1 Idiopathic
1.2 Heritable
   1.2.1 BMPR2 mutation
   1.2.2 Other mutations
1.3 Drugs and toxins induced
1.4 Associated with:
   1.4.1 Connective tissue disease
   1.4.2 HIV infection
   1.4.3 Portal hypertension
   1.4.4 Congenital heart disease (Table 6)
   1.4.5 Schistosomiasis
2.1 Left ventricular systolic dysfunction
2.2 Left ventricular diastolic dysfunction
2.3 Valvular disease
2.4 Congenital/acquired left heart inﬂow/outﬂow tract obstruction    
      and congenital cardiomyopathies
2.5 Other
3.1 Chronic obstructive pulmonary disease
3.2 Interstitial lung disease
3.3 Other pulmonary diseases with mixed restrictive and
      obstructive pattern
3.4 Sleep-disordered breathing
3.5 Alveolar hypoventilation disorders
3.6 Chronic exposure to high altitude
3.7 Developmental lung diseases (Web Table III)
4.1 Chronic thromboembolic pulmonary hypertension
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elevation of PVR is due to an increase in PA vasomotor tone and/or to fixed structural obstructive
remodelling of the PA resistance vessels [59]; the former component of reactive PH is reversible under
acute pharmacological testing, while the latter, characterized by medial hypertrophy and intimal
proliferation of the pulmonary arteriole, does not respond to the acute challenge [60].
• Group 3: PH due to lung diseases and/or hypoxia: The mechanisms involved include hypoxic vasoconstriction,
mechanical stress of hyperinflated lungs, loss of capillaries, inflammation and toxic effects of cigarette smoke.
There are also data supporting an endothelium-derived vasoconstrictor–vasodilator imbalance.
• Group 4: PH due to chronic PA obstruction: Non-resolution of acute embolic masses that later undergo
fibrosis leading to mechanical obstruction of pulmonary arteries is believed to be an important
pathobiological process in CTEPH. However, a mechanistic view of CTEPH as a disease exclusively
caused by obliteration of central pulmonary arteries by pulmonary emboli is too simplistic. Pulmonary
Web Table II Anatomical-pathophysiological classification of
congenital systemic-to-pulmonary shunts associated with
pulmonary arterial hypertension (adapted from Simonneau
et al. [2])
1. Type
2. Dimension (specify for each defect if more than one congenital 
    heart defect exists)
3. Direction of shunt
4. Associated cardiac and extracardiac abnormalities
5. Repair status
1.1 Simple pre-tricuspid shunts
   1.1.1 Atrial septal defect (ASD)
      1.1.1.1 Ostium secundum
      1.1.1.2 Sinus venosus
      1.1.1.3 Ostium primum
   1.1.2 Total or partial unobstructed anomalous pulmonary venous
            return
1.2 Simple post-tricuspid shunts
   1.2.1 Ventricular septal defect (VSD)
   1.2.2 Patent ductus arteriosus
1.3 Combined shunts
      Describe combination and deﬁne predominant defect
1.4 Complex congenital heart disease
   1.4.1 Complete atrioventricular septal defect
   1.4.2 Truncus arteriosus
   1.4.3 Single ventricle physiology with unobstructed pulmonary    
             blood ﬂow
   1.4.4 Transposition of the great arteries with VSD (without
            pulmonary stenosis) and/or patent ductus arteriosus
   1.4.5 Other
2.1 Haemodynamic (specify Qp/Qs)a
   2.1.1 Restrictive (pressure gradient across the defect)
   2.1.2 Non-restrictive
2.2 Anatomicb
   2.2.1 Small to moderate (ASD ≤2.0 cm and VSD ≤1.0 cm)





5.2 Palliated (specify type of operation/s, age at surgery)
5.3 Repaired (specify type of operation/s, age at surgery)
aRatio of pulmonary (Qp) to systemic (Qs) blood flow. bThe size
applies to adult patients.
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embolism (PE) could be followed by a pulmonary vascular remodelling process modified by infection,
immune phenomena, inflammation and circulating and vascular-resident progenitor cells. Only a few
specific thrombophilic factors, such as antiphospholipid antibodies, lupus anticoagulant and elevated
factor VIII, have been statistically associated with CTEPH, and no abnormalities of fibrinolysis have
been consistently demonstrated. Microvascular disease may be related to shear stress in non-obstructed
areas, post-capillary remodelling related to bronchial-to-pulmonary venous shunting, pressure,
inflammation and release of cytokines and vasculotrophic mediators [55].
• Group 5: By definition, the pathobiology in this group is unclear or multifactorial.
Pulmonary arterial hypertension screening programme
The prognosis of PAH is significantly worse in patients with advanced disease [61, 62]. PAH therapies
delay clinical worsening [63] and data are accumulating suggesting that early treatment improves
long-term outcome [13, 63, 64] Screening is the systematic application of a test to identify individuals at
sufficient risk of a specific disorder to warrant further investigation or direct preventive action among
persons who have not sought medical attention on account of symptoms of that disorder [65]. Therefore
screening for PH/PAH applies to asymptomatic individuals belonging to groups in which PH/PAH is
highly prevalent, such as patients with systemic sclerosis (SSc) [66, 67], BMPR2 mutation carriers or
relatives of patients with heritable PAH (HPAH) [68], patients with sickle cell disease (SCD) and patients
with portal hypertension referred for liver transplantation [69].
A screening method should use tools that are non-invasive, reproducible, associated with a high negative
predictive value for the condition and cost effective [61]. In PH/PAH, these tools include pulmonary
function tests (PFTs), circulating biomarkers and echocardiography. In SSc, PFTs have long been used as a
screening tool, especially changes in diffusing capacity of the lung for carbon monoxide (DLCO) [70, 71].
Web Table III Developmental lung disease associated with
pulmonary hypertension (adapted from Ivy et al. [3])
1. Congenital diaphragmatic hernia
2. Bronchopulmonary dysplasia
3. Alveolar capillary dysplasia (ACD)
7. Pulmonary interstitial glycogenosis
8. Pulmonary alveolar proteinosis
9. Pulmonary lymphangiectasia
4. ACD with misalignment of veins
5. Lung hypoplasia (“primary” or “secondary”)
6. Surfactant protein abnormalities
    a. Surfactant protein B deﬁciency
    b. Surfactant protein C deﬁciency
    c. ATP-binding cassette A3 mutation
    d. Thyroid transcription factor 1/Nkx2.1 homeobox mutation
Web Table IV Route of administration, half-life, dose ranges, increments, and duration of














































Inh: inhaled; i.v.: intravenous; NO: nitric oxide; ppm: parts per million. aClass of recommendation. bLevel of
evidence. cReference(s) supporting recommendations. dInitial dose and maximal dose suggested.
eIncrements of dose by each step. fDuration of administration on each step. gFor NO a single step within the
dose range is suggested.
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Web Table V Functional classification of pulmonary
hypertension modified after the NYHA functional
classification according to the WHO 1998 [9].
Class I – Patients with pulmonary hypertension but without 
resulting limitation of physical activity. Ordinary physical activity 
does not cause undue dyspnoea or fatigue, chest pain or near 
syncope.
Class III – Patients with pulmonary hypertension resulting in 
marked limitation of physical activity. They are comfortable at rest. 
Less than ordinary activity causes undue dyspnoea or fatigue, chest 
pain or near syncope.
Class II – Patients with pulmonary hypertension resulting in slight
limitation of physical activity. They are comfortable at rest. Ordinary
physical activity causes undue dyspnoea or fatigue, chest pain or 
near syncope.
Class IV – Patients with pulmonary hypertension with inability to
carry out any physical activity without symptoms. These patients
manifest signs of right heart failure. Dyspnoea and/or fatigue may 
even be present at rest. Discomfort is increased by any physical 
activity.
NYHA: New York Heart Association; WHO: World Health
Organization.
Web Table VIA Characteristics of randomised controlled trials with pulmonary arterial
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6MWD: 6-minute walking distance; PVR: pulmonary vascular resistance; SaO2: finger oxygen saturation;
TTCW: time to clinical worsening.
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An increased risk of PAH has been shown in adult SSc patients with a DLCO <60% of predicted [67].
There is now additional evidence suggesting that biomarkers [N-terminal pro-brain natriuretic peptide
(NT-proBNP)], alone [72, 73] or in combination with PFTs [74], may identify patients at higher risk to
present SSc-PAH. Finally, a recent study in patients undergoing right heart catheterization (RHC) as part
of the evaluation of SSc suggested that, in the absence of PH, an increase in the transpulmonary pressure
gradient (TPG) was associated with a higher risk of subsequently developing pre-capillary PH [75].
Echocardiography at rest remains the best way to estimate elevated pulmonary pressures. It has been used
in large SSc-PAH screening programmes [67, 76] by stratifying patients according to the level of PAPs
estimated by the tricuspid regurgitant velocity (TRV). The recommendations for diagnostic management
according to echocardiographic probability of PH in asymptomatic patients with or without risk factors
for PAH or CTEPH are reported in Online Table IX. Conversely, exercise echocardiography has technical
and methodological limitations and is not recommended for PH/PAH screening [77–81].
Recent studies in SSc and SCD have demonstrated that asymptomatic PAH patients detected by screening
can be missed by Doppler echocardiography (false negative), emphasizing the need for a multitest
approach. In SSc, a composite measure has been proposed in the DETECT study [67]. In this study, adult
SSc patients with >3-years disease duration and a DLCO <60% of predicted underwent non-invasive testing
and RHC. A stepwise detection approach has been proposed with six simple clinical and biological
assessments in step 1 of the algorithm determining referral to echocardiography. In step 2, the step 1
prediction score and two echocardiographic variables determined referral to RHC. The DETECT algorithm
recommended RHC in 62% of patients (referral rate) and missed 4% of PAH patients (false negatives).
Web Table VIB Characteristics of randomised controlled trials with pulmonary arterial
hypertension drugs interfering with the nitric oxide pathway (Soluble guanylate cyclase
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treated group
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bosentan treated 
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TTCW improved
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227 12 No 6MWD















No 6MWD 6MWD improved






6MWD: 6-minute walking distance; SAE: serious adverse events; TTCW: time to clinical worsening;
TT: treadmill test. aThis drug is not approved by the EMA at the time of publication of these guidelines.
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Of those, 19% had RHC-confirmed PAH [67]. This screening approach is interesting, but there is currently
no information on long-term outcomes in asymptomatic SSc-PAH patients screened thanks to the
Web Table VIC Characteristics of randomised controlled trials with pulmonary arterial
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6MWD: 6-minute walking distance; CW: clinical worsening; PVR: pulmonary vascular resistance;
TT: treadmill test; TTCW: time to clinical worsening. aThis drug is not approved by the EMA at the time
of publication of these guidelines.
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DETECT algorithm. Of note, the DETECT study did not provide recommendations regarding patients with
a DLCO ⩾60% and its findings need to be validated in another cohort. Beyond initial screening, the
frequency of non-invasive tests is unclear in asymptomatic subjects with a high risk of developing incident
PAH. Annual screening with echocardiography, DLCO and NT-proBNP has been proposed in SSc patients
[66, 82].
Pre-capillary PH is a known complication of SCD, but the prevalence SCD-PH has been overestimated in
echocardiography based studies [83]. Two recent studies [84, 85] employed similar methodologies and
referred all patients with a screening TRV ⩾2.5 m/s on echocardiography for confirmatory RHC. The
prevalence of PH ranged from 6.2 to 10% (post-capillary PH in 3.3 and 6.2%, and pre-capillary PH in 2.9
and 3.8%, respectively). An exploratory post-hoc analysis found that calibrating TRV to ⩾2.9 m/s or TRV
between 2.5 and 2.8 m/s plus either NT-proBNP >164.5 pg/ml or a 6-minute walk distance (6MWD) <333
m reduced the number of RHC referrals compared with a single TRV threshold ⩾2.5 m/s [84].
BMPR2 mutation carriers have a lifetime risk of developing PAH of approximately 20% [68, 86]. It is
currently not possible to predict those who will ultimately develop PAH, although women are at increased
risk compared with men [86]. In patients carrying a BMPR2 mutation, the frequency of screening is
unknown. At present, asymptomatic individuals who test positive for PAH-causing mutations and
first-degree relatives of HPAH patients in whom no causal mutations have been identified are offered
yearly screening echocardiography. An ongoing longitudinal study should clarify issues such as optimal
screening strategies and predictors of progression to PAH in asymptomatic BMPR2 carriers [DELPHI-2
(NCT01600898)].
PAH screening is recommended in patients presenting for liver transplantation assessment. Doppler
echocardiography is the only screening modality that has been systematically evaluated in porto-pulmonary
hypertension (PoPH) [87]. The recommendations for PAH screening are reported in Web Table X.
Quality of life measurements
Quality of life measures describe the patient’s own perception of their health and how it affects them. This
information is complementary to the typical clinical information collected by healthcare professionals.
General quality of life questionnaires have been shown to be useful in PAH, including the 36-item Short
Form Health Survey (SF-36) [91], whose Physical Component Score was prognostic in one study [92]. Since
many generic quality of life questionnaires may not reflect well clinical status in PAH [93], disease-specific
questionnaires have been developed and validated. These include the Cambridge Pulmonary Hypertension
Outcome Review (CAMPHOR) [94–96], emPHasis-10 [97], Minnesota Living with Heart Failure – PH [98,
99] and Pulmonary Arterial Hypertension Symptom Scale (PAHSS) [100] questionnaires. Since there are
no head-to-head comparisons it is not possible to recommend one over the others.
Appendix
Task Force Members: Nazzareno Galiè (ESC Chairperson) (Italy), Marc Humbert (ERS Chairperson)
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Caution is required in the co-administration of ambrisentan with 
ketoconazole and cyclosporine
Sildenaﬁl levels fall 50%; bosentan levels increase 50%. May not 
require dose adjustments of either drug.
CYP3A4 substrate Cyclosporine
Cyclosporine levels fall 50%; bosentan levels increase 4-fold. 
Combination contraindicted.
CYP3A4 substrate Erythromycin
Bosentan levels increase. May not require dose adjustment of 
bosentan during a short course.
CYP3A4 substrate 
+bile salt pump inhibitor Glibenclamide
Increase incidence of elevated aminotransferases. potential 
decrease of hypoglycaemic effect of glibenclamide. Combination 
contraindicted.
CYP2C9 and CYP3A4 substrate Fluconazole, amiodarone Bosentan levels increase considerably. Combination contraindicted.
CYP2C9 and CYP3A4 inducers Rifampicin, phenytoin Bosentan levels decrease by 58%. Need for dose adjustment uncertain.
CYP2C9 inducer HMG CoA reductase inhibitors
Simvastatin levels reduce 50%; similar effects likely with 
atorvastatin. Cholesterol level should be monitored.
CYP2C9 inducer Warfarin
Increase warfarin metabolism, may need to adjust warfarin dose. 
Intensiﬁed monitoring of warfarin recommended following initiation 
but dose adjustments usually unnecessary.
CYP2C9 and CYP3A4 inducers Hormonal 
contraceptives Hormone levels decrease. Contraception unreliable.
Macitentan To be determined
Selexipag To be determined
Sildenaﬁl [43]
Sildenaﬁl levels fall 50%; bosentan levels increase 50%. May not 
require dose adjustments of either drug.
CYP3A4 substrate Ketoconazole Bosentan levels increase 2-fold
CYP3A4 substrate Bosentan
May increase simvastin/atorvastatin levels through competition for 
metabolism. Sildenaﬁl levels may increase. Possible increased risk 
of rhabdomyolysis
CYP3A4 substrate HMG CoA reductase inhibitors
Ritonavir and saquinovir increase sildenaﬁl levels markedly.CYP3A4 substrate HIV protease inhibitors
Sildenaﬁl level may fall.CYP3A4 inducer Phenytoin
Sildenaﬁl levels increase. May not require dose adjustment for a 
short course.
CYP3A4 substrate Erythromycin
Sildenaﬁl levels increase. May not require dose adjustment.CYP3A4 substrate Ketoconazole
Sildenaﬁl levels increase. May not require dose adjustment.CYP3A4 substrate Cimetidine
Profound systemic hypotension, combination contraindicated.cGMP Nitrates, Nicorandil, 
Molsidomine
Hypotension, severe side effects, combination contraindicated.cGMP Sildenaﬁl, other PDE-5 
inhibitors
Tadalaﬁl exposure decreases by 42%, no signiﬁcant changes in 
bosentan levels [44]. May not require dose adjustment.CYPA4 substrate BosentanTadalaﬁl [44]
Profound systemic hypotension, combination contraindicated.cGMP Nitrates, Nicorandil
Riociguat [18]
Profound systemic hypotension, combination contraindicated.cGMP Nitrates, Nicorandil
cGMP: cyclic guanosine monophosphate; PDE-5: phosphodiesterase type-5. aThis table is adapted from National Pulmonary Hypertension
Centres of the UK and Ireland. Consensus Statement on the Management of Pulmonary Hypertension in Clinical Practice in the UK and
Ireland. Heart 2008;94(suppl I):i1–41. See also updated official prescribing information for each compound.
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Web Table VIII Conditions of clinical group 5 that may cause pulmonary hypertension
Haematological disorders
a. Chronic haemolytic anaemia   
    The common feature of the haemolytic anaemias is that when there is intravascular haemolysis, there is release of cell-free haemoglobin    
    into the plasma which scavenges the nitric oxide. A loss of nitric oxide, the physiological vasodilator of the pulmonary circulation, may 
    cause vasoconstriction and vascular obstructive pathologic changes.
 
b. Sickle cell anaemia
    Cells containing sickle cell haemoglobin (HbS) may sickle and be trapped in the microcirculation, resulting in local obstruction to blood  
    flow. An additional factor leading to pulmonary hypertension (PH) is that these patients can suffer either functional or surgical asplenia,    
    putting them at risk for thromboembolism and chronic thromboembolic pulmonary hypertension (CTEPH). There are, however, a few  
    small uncontrolled studies, but the results of treatments such as bosentan and sildenafil are modest at best.
 
c. Beta-thalassaemia
    PH in patients with thalassaemia is also multifactorial, involving intravascular haemolysis (see above), changes in the coagulation system, 
    and local inflammation.
 
d. Hereditary spherocytosis/stomatocytosis
    Hereditary stomatocytosis is a rare autosomal red cell membrane disorder and the red cells are subject to intravascular haemolysis. In    
    addition, there is a high risk of thrombotic complications but, once again, this is often in association with splenectomy which is done to   
    prevent the haemolysis.
 
e. Myeloproliferative disease
    Chronic myeloproliferative disease (CMPD) is associated with PH. There are thought to be 2 main aetiologies.
      1. CMPD may have excess risk of venous thrombosis.
      2. CMPD may have pre-capillary proliferative vasculopathy. It is of interest that dasatinib, a tyrosine kinase inhibitor, which is one of    
          treatments for chronic myeloid leukaemia, also appears to cause partially reversible PH [45, 46].
 
f. Splenectomy
   Splenectomy causes an increased risk of CTEPH and also even idiopathic pulmonary arterial hypertension.
Metabolic disorders
a. Thyroid disease
    PH associated with hypo- or hyper-thyroidism [50].
 
b. Glycogen storage diseases
    Pathogenesis of PH unknown but may include pulmonary veno-occlusive disease. Enzyme replacement therapy seems to have little 
    effect, unlike Gaucher’s disease (see below).
 
c. Gaucher’s disease
    Approximately 30% of untreated patients with Gaucher’s disease develop PH which is caused by a combination of factors including    
    plugging of the vasculature by the abnormal macrophages, abnormal pulmonary vascular cell proliferation, and asplenia (see above).
    Treatment with enzyme replacement therapy (ERT), which is now the dominant therapy for Gaucher’s disease, may improve the PH.    
    However, ERT initiation can also unmask underlying PH.
Systemic disorders associated with pulmonary hypertension
These disorders include sarcoidosis, histiocytosis, lymphangiomyomatosis and neurofibromatosis.
 
a. Sarcoidosis
    PH occurs in 5–15% [47]. The cause of PH in sarcoidosis is multifactorial, including fibrosing lung disease, granulomata in the pulmonary 
    arteries, fibrosing mediastinitis, pulmonary vasculitis, portopulmonary hypertension, and pulmonary veno-occlusive disease [48].
 
b. Langerhans cell histiocytosis (LCH)
    PH associated with parenchymal lung disease itself related to smoking.
 
c. Lymphangioleiomyomatosis (LAM)
    PH associated with parenchymal lung disease occurs in approximately 7% of unselected patients with LAM.
Other disorders
a. Chronic renal failure
    PH is very common in end-stage renal disease and is multifactorial: anaemia, arteriovenous (A.V) fistulae (used for haemodialysis), both   
    of which cause a high output state. It may be due to proliferative vascular dysfunction, related in part to uraemia which is also known to 
    affect the systemic vessels. Most observers agree that PH in chronic renal failure is mostly venous in origin due to left ventricular 
    dysfunction, which is in turn due to myocardial damage caused by the processes of renal failure.
 
b. Fibrosing mediastinitis
    In PH due to fibrosing mediastinitis, the main pathology is obliteration of central veins and arteries by the fibrosing proxess [47,48].
 
c. Tumours
    Approximately 25% of patients dying with cancer die with tumour emboli in the pulmonary circulation. Tumours seem to be that 
    particularly associated with PH are gastric, breast, ovary, lung, kidney and colon. Tumour cells migrate to the pulmonary circulation  
    where they seem to cause a microangiopathy.
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Hélène Bouvaist (France), Héctor Bueno (Spain), Robert A. Byrne (Germany), Scipione Carerj (Italy),
Graça Castro (Portugal), Çetin Erol (Turkey), Volkmar Falk (Germany), Christian Funck-Brentano
(France), Matthias Gorenflo (Germany), John Granton (Canada), Bernard Iung (France), David G. Kiely
(UK), Paulus Kirchhof (Germany/UK), Barbro Kjellstrom (Sweden), Ulf Landmesser (Switzerland), John
Lekakis (Greece), Christos Lionis (Greece), Gregory Y.H. Lip (UK), Stylianos E. Orfanos (Greece), Myung
H. Park (USA), Massimo F. Piepoli (Italy), Piotr Ponikowski (Poland), Marie-Pierre Revel (France), David
Rigau (ERS methodologist) (Switzerland), Stephan Rosenkranz (Germany), Heinz Völler (Germany), and
Jose Luis Zamorano (Spain).
ESC Associations: Acute Cardiovascular Care Association (ACCA), European Association for
Cardiovascular Prevention and Rehabilitation (EACPR), European Association of Cardiovascular Imaging
(EACVI), European Association of Percutaneous Cardiovascular Interventions (EAPCI), European Heart
Rhythm Association (EHRA), Heart Failure Association (HFA).
ESC Councils: Council for Cardiology Practice (CCP), Council on Cardiovascular Nursing and Allied
Professions (CCNAP), Council on Cardiovascular Primary Care (CCPC).
Web Table IX Diagnostic management suggested according to echocardiographic probability of pulmonary hypertension in







Without risk factors or associated 
condition for PAH or CTEPHd,e
No work up for PAH required
Echo follow-up should be considered
RHC should be consideredf
Without risk factors or associated 
conditions for PAH or CTEPHd,e
Echo follow-up may be considered









If associated scleroderma, 

















CTEPH: chronic thromboembolic pulmonary hypertension; Echo: echocardiographic; EO: expert opinion; PAH: pulmonary arterial
hypertension; PH: pulmonary hypertension; RHC: right heart catheterization. aClass of recommendation. bLevel of evidence. cReference(s)
supporting recommendations. dApplies to accidental findings during echocardiography performed for indications other than suspected PH.
Recommendations regarding prospective institutional screening programmes for PAH or CTEPH are described in a dedicated section of the
guidelines. eThese recommendations do not apply to patients with diffuse parenchymal lung disease or left heart disease. fDepending on the
presence of risk factors for PH group 2, 3 or 5. Further investigation strategy may differ depending on whether risk factors/associated
conditions suggest higher probability of PAH or CTEPH – see diagnostic algorithm (Figure 1).
Web Table X Recommendations for pulmonary arterial hypertension screening
Recommendations







Resting echocardiography is recommended as a screening test in BMPR2 mutation carriers or ﬁrst-degree 
relatives of patients with HPAH and in patients with PoPH referred for liver transplantation. I C [69, 89]
Systemic sclerosis patients with a mean PAP ranging from 21 to 24 mmHg should be closely monitored, because 
of a higher risk of PAH. IIa B [75]
Initial screening using the stepwise DETECT algorithm may be considered in adult systemic sclerosis patients 
with >3 years’ disease duration and a DLCO <60% predicted. IIb B [67]
Annual screening with echocardiography, PFTs and biomarkers may be considered in patients with systemic 
sclerosis. IIb B [66, 90]
Exercise echocardiography is not recommended to predict PH in high risk population. III C [79]
In individuals who test positive for PAH-causing mutations and ﬁrst-degree relatives of HPAH cases may be 
considered to have an annual screening echocardiogram. IIb C [68]
A combined approach (including biomarkers, PFTs and echocardiography) should be considered to predict PH in 
systemic sclerosis. IIa B [66, 67]
DLCO: diffusing capacity of the lung for carbon monoxide; HPAH: heritable PAH; PAP: pulmonary arterial pressure; PAH: pulmonary arterial
hypertension; PFTs: pulmonary function tests; PH: pulmonary hypertension: PoPH: portopulmonary hypertension. aClass of
recommendation.bLevel of evidence. cReference(s) supporting recommendations.
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ESC Working Groups: Cardiovascular Pharmacotherapy, Cardiovascular Surgery, Grown-up Congenital
Heart Disease, Pulmonary Circulation and Right Ventricular Function, Valvular Heart Disease.
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